What happened with ACAD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Acadia Pharmaceuticals sells two medicines: NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide) for Rett syndrome. NUPLAZID brings in most of its revenue, with DAYBUE providing the rest. Nearly all revenue comes from North America.
The company earns money by selling these drugs to intermediaries that supply patients and healthcare facilities. In the United States, specialty pharmacies and distributors buy NUPLAZID, with a small group of customers accounting for most of its sales. U.S. DAYBUE sales go through a single wholesale distributor that also provides specialty pharmacy services. Sales depend on doctors prescribing the medicines, patients continuing treatment, and private insurers and government payors covering their cost.
Acadia developed NUPLAZID and licenses DAYBUE rights from Neuren, which receives sales royalties and may receive milestone payments. Acadia outsources drug manufacturing, so it also depends on outside suppliers for commercial supply. It cannot promote its drugs for uses outside their approved labeling. Selling trofinetide in additional countries requires local regulatory approval; it cannot yet market the drug in the EU or Japan.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Acadia’s results hinge on NUPLAZID demand and DAYBUE adoption; watch Neuren, absent from this list, which shares directly in DAYBUE’s economics through royalties and sales milestones.
Taysha Gene Therapies’ pivotal TSHA-102 trial could bring competition for the Rett syndrome patients who use Acadia’s DAYBUE. Watch results for this experimental one-time gene therapy, designed to deliver a functional MECP2 gene to central nervous system cells.
Neurogene’s NGN-401 could compete for Rett syndrome patients currently treated with Acadia’s DAYBUE. Neurogene has no approved product or commercial product revenue yet, so its Phase 3 gene-therapy results—not current sales—are the news to watch.
Acadia shares both the spending and potential upside of its SYNGAP1 medicines with Stoke Therapeutics: the companies jointly develop them and split worldwide costs and future profits equally. Progress in that program matters to Acadia’s development spending as well as its future earnings.
Supernus Pharmaceuticals and Acadia serve the same underlying Parkinson’s patient population, but Supernus sells medicines for movement complications while Acadia sells NUPLAZID for hallucinations and delusions. Adoption of Supernus’s Parkinson’s medicines offers a view of treatment uptake in that patient group, not a direct measure of NUPLAZID demand.
MapLight Therapeutics’ ML-007C-MA competes in development with Acadia’s ACP-204 to treat Alzheimer’s disease psychosis, rather than with Acadia’s current product sales. Watch MapLight’s Phase 2 VISTA results, which it expected in the second half of 2027.
Neurocrine Biosciences offers a business comparison for Acadia: its INGREZZA-led neurological medicines and CRENESSITY rare-disease launch parallel Acadia’s NUPLAZID and DAYBUE businesses. Specialist adoption and payer access for these U.S. specialty medicines are the shared issues to watch.
Ovid Therapeutics’ KCC2 drug pipeline targets Parkinson’s disease psychosis, putting it in potential competition with Acadia’s NUPLAZID sales to that patient group. Watch progress in those psychosis programs, rather than Ovid’s separate seizure treatments.
Teva’s generic-drug business is tied to potential competition for Acadia’s NUPLAZID through pimavanserin patent litigation. Teva’s claims were stayed and it is bound by the result against the remaining defendants, making that litigation outcome the key news to watch.
Axsome Therapeutics already sells AUVELITY to U.S. patients with major depressive disorder, the patient group Acadia’s depression treatments in development would compete to serve. AUVELITY’s uptake is the relevant commercial comparison for Acadia’s depression pipeline, not Axsome’s sleepiness or migraine products.
Acadia relies on Thermo Fisher Scientific’s Patheon subsidiary to make NUPLAZID 10 mg tablets and 34 mg capsules for U.S. commercial use, paying an outside manufacturer rather than building its own facilities. Patheon’s ability to supply those products is the part of Thermo Fisher’s business that matters directly to Acadia.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher’s report may offer a supply-chain signal for Acadia if it gives detail on Patheon, the subsidiary that makes NUPLAZID tablets and capsules for U.S. use.
Look for disclosures about Patheon’s manufacturing operations, capacity, or supply; Thermo Fisher’s overall results are not a direct measure of Patheon. Evidence of steady operations would support this outsourced route for supplying Acadia’s NUPLAZID tablets and capsules. Disclosed disruption or capacity limits would raise the risk of constrained supply or higher costs for Acadia. If the report gives no Patheon-specific information, its overall figures cannot settle the supply question.
Stoke Therapeutics, Inc. earningsSTOK
Stoke Therapeutics shares global costs and potential profits from the SYNGAP1 medicines it develops with Acadia, so its report may show how that shared program is progressing.
Look for what Stoke reports about progress in the jointly developed SYNGAP1 medicines, and whether that progress comes with changes in development spending. Advancement could improve the future opportunity attached to Acadia’s shared investment, but both companies still bear their agreed development costs; delay or setbacks would weaken the potential return without necessarily removing costs at once. The takeaway is whether the program’s future opportunity still supports the investment Acadia shares.
Taysha Gene Therapies, Inc. earningsTSHA
Progress in Taysha Gene Therapies’ pivotal TSHA-102 trial could strengthen a potential future competitor to Acadia’s DAYBUE for Rett syndrome.
Focus on Taysha’s disclosures about the pivotal TSHA-102 trial, not on treating development news as product sales. Meaningful trial progress would make this one-time gene therapy a more credible future option and a more concrete potential competitor to DAYBUE; weak data or delays would leave that threat less established. Trial progress alone would not mean patients are already switching away from DAYBUE.
Acadia Pharmaceuticals Inc. earningsThis company
Acadia earns product revenue from NUPLAZID and DAYBUE, and this report will show whether DAYBUE sales growth is keeping pace as standard manufacturing costs replace zero-cost inventory, while revealing whether NUPLAZID sales are holding up.
Read sales for each product alongside cost of product sales, with particular attention to DAYBUE: as its remaining zero-cost inventory is used up, standard manufacturing costs flow into that expense. DAYBUE sales growth with costs still in the company’s expected mid-single-digit to high-single-digit share of sales would show that manufacturing costs are not eating heavily into added sales; slower sales or a rising cost share would mean less of that growth reaches product gross profit. Then check whether NUPLAZID sales hold up: a decline would leave DAYBUE carrying more of the growth burden, while steady NUPLAZID sales alongside DAYBUE growth that covers its costs would make the product revenue base firmer.
Ovid Therapeutics Inc. earningsOVID
Progress in Ovid Therapeutics’ KCC2 programs could make it a stronger potential future competitor to Acadia’s NUPLAZID for Parkinson’s disease psychosis.
Watch Ovid’s updates on its KCC2 psychosis programs, not its separate seizure programs. Progress would make Ovid a more credible potential competitor to NUPLAZID for Parkinson’s disease psychosis; limited progress or delay would leave that competition more remote. Development news does not show whether current prescriptions for NUPLAZID are changing.
